Karyopharm Therapeutics was founded in the late, premier biotech innovation era by visionary scientists and entrepreneurs aiming to pioneer nuclear transport modulation as a therapeutic approach. Over the decades, the enterprise advanced from early-stage discovery into a clinical-stage and eventually a commercial-stage biopharmaceutical organization. It achieved major regulatory milestones with the approval of its lead oncology product, completed strategic public market offerings, and expanded its global footprint through extensive clinical trial pipelines.